Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation

Bone Marrow Transplant. 2016 Jun;51(6):850-2. doi: 10.1038/bmt.2015.346. Epub 2016 Feb 1.

Authors

J A Yared¹, N Hardy¹, Z Singh², S Hajj³, A Z Badros¹, M Kocoglu¹, S Yanovich¹, E A Sausville¹, C Ujjani⁴, K Ruehle¹, C Goecke¹, M Landau¹, A P Rapoport¹

Affiliations

¹ Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
² Department of Pathology, University of Maryland, Baltimore, MD, USA.
³ Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore, MD, USA.
⁴ Division of Hematology/Oncology, Lombardi Cancer Center, Georgetown University, Washington DC, WA, USA.

PMID: 26828905
DOI: 10.1038/bmt.2015.346

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Disease Progression
Female
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease / drug therapy
Hodgkin Disease / therapy*
Humans
Imaging, Three-Dimensional
Immunotherapy / methods
Middle Aged
Neoplasm Recurrence, Local
Nivolumab
Positron-Emission Tomography
Programmed Cell Death 1 Receptor / metabolism
Transplantation, Homologous
Treatment Outcome

Substances

Antibodies, Monoclonal
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab